Abstract Number 581: Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.
Abstract Number 607: TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study.
Abstract Number 1080: Tumor Treating Fields (TTFields) application induces a pro-inflammatory phenotype in macrophages.
News 
Market Data 
Discover 
AI
